Victory Capital Management Inc Arcus Biosciences, Inc. Transaction History

Victory Capital Management Inc

  • $95.8 Billion
  • Q2 2024

A detailed history of Victory Capital Management Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 49,702 shares of RCUS stock, worth $765,907. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,702
Previous 75,326 34.02%
Holding current value
$765,907
Previous $1.42 Million 46.84%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024
SELL
$14.59 - $18.48 $373,854 - $473,531
-25,624 Reduced 34.02%
49,702 $756,000
Q1 2024

May 03, 2024
SELL
$14.83 - $20.18 $431,360 - $586,975
-29,087 Reduced 27.86%
75,326 $1.42 Million
Q4 2023

Feb 05, 2024
BUY
$13.43 - $19.63 $487,670 - $712,804
36,312 Added 53.32%
104,413 $1.99 Million
Q3 2023

Nov 06, 2023
SELL
$17.62 - $23.54 $106,812 - $142,699
-6,062 Reduced 8.17%
68,101 $1.22 Million
Q2 2023

Jul 27, 2023
SELL
$16.97 - $22.03 $337,753 - $438,463
-19,903 Reduced 21.16%
74,163 $1.51 Million
Q1 2023

May 02, 2023
BUY
$15.96 - $23.15 $453,311 - $657,529
28,403 Added 43.26%
94,066 $1.72 Million
Q4 2022

Feb 10, 2023
BUY
$19.7 - $35.71 $59,494 - $107,844
3,020 Added 4.82%
65,663 $1.36 Million
Q4 2022

Feb 09, 2023
BUY
$19.7 - $35.71 $886,165 - $1.61 Million
44,983 Added 254.72%
62,643 $1.3 Million
Q3 2022

Nov 02, 2022
BUY
$23.23 - $30.07 $44,090 - $57,072
1,898 Added 12.04%
17,660 $462,000
Q2 2022

Aug 01, 2022
SELL
$17.23 - $37.73 $25,310 - $55,425
-1,469 Reduced 8.53%
15,762 $399,000
Q1 2022

May 04, 2022
BUY
$28.92 - $41.83 $300,305 - $434,362
10,384 Added 151.66%
17,231 $417,000
Q4 2021

Feb 07, 2022
SELL
$31.38 - $48.47 $13,681 - $21,132
-436 Reduced 5.99%
6,847 $277,000
Q3 2021

Nov 02, 2021
SELL
$26.93 - $37.68 $1.71 Million - $2.4 Million
-63,577 Reduced 89.72%
7,283 $254,000
Q2 2021

Aug 03, 2021
SELL
$22.75 - $35.77 $33.2 Million - $52.2 Million
-1,459,488 Reduced 95.37%
70,860 $1.95 Million
Q1 2021

May 04, 2021
BUY
$26.16 - $41.39 $10.4 Million - $16.5 Million
397,786 Added 35.12%
1,530,348 $43 Million
Q4 2020

Feb 01, 2021
SELL
$17.0 - $32.36 $951,949 - $1.81 Million
-55,997 Reduced 4.71%
1,132,562 $29.4 Million
Q3 2020

Nov 09, 2020
BUY
$17.14 - $25.47 $5.07 Million - $7.54 Million
295,955 Added 33.16%
1,188,559 $20.4 Million
Q2 2020

Aug 07, 2020
BUY
$13.97 - $36.56 $12.4 Million - $32.5 Million
887,758 Added 18319.4%
892,604 $22.1 Million
Q1 2020

May 04, 2020
SELL
$8.78 - $19.28 $965 - $2,120
-110 Reduced 2.22%
4,846 $67,000
Q4 2019

Feb 04, 2020
BUY
$7.33 - $10.79 $3,408 - $5,017
465 Added 10.35%
4,956 $44,000
Q3 2019

Nov 12, 2019
BUY
$6.44 - $10.18 $28,922 - $45,718
4,491 New
4,491 $41,000

Others Institutions Holding RCUS

# of Institutions
207
Shares Held
49M
Call Options Held
173K
Put Options Held
151K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.11B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email